Effects of Psilocybin in Anorexia Nervosa
Brief Summary
This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.
Study Design
Study type: | Interventional |
---|---|
Status: | Recruiting |
Study results: | No Results Available |
Age: | 18 Years to 65 Years (Adult, Older Adult) |
Enrollment: | 18 () |
Funded by: | Other |
Masking |
Clinical Trial Dates
Start date: | Aug 26, 2019 | |
---|---|---|
Primary Completion: | Dec 01, 2022 | |
Completion Date: | Dec 01, 2022 | |
Study First Posted: | Aug 12, 2019 | |
Results First Posted: | Aug 30, 2020 | |
Last Updated: | Oct 26, 2021 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 18 |
Maximum Age: | 65 |
This clinical trial is recruiting
Are you interested in participating in this trial or others? We'd love to help.
More Details
NCT Number: | NCT04052568 |
---|---|
Other IDs: | IRB00182516 |
Study URL: | https://ClinicalTrials.gov/show/NCT04052568 |
Last updated: Jun 16, 2022